However, since both Tyk2 and JAK1 are involved in IL-10 signaling and promote IL-10 activation, JAK1 inhibitors such as upadacitinib may, like Tyk2 inhibitors, impair the IL-10 signaling pathway and IL-10 activation, potentially weakening the T-cell immune response against P. aeruginosa and having the possibility of GN development [20]. The gene discussed is JAK1; the disease is ganglioneuroma.